



**World Health  
Organization**

INN Working Document 18.435  
31/05/2018

**Addendum<sup>1</sup> to**  
***"The use of stems in the selection of International  
Nonproprietary names (INN) for pharmaceutical  
substances"*** WHO/EMP/RHT/TSN/2013.1

***Programme on International Nonproprietary Names (INN)***

***Technologies Standards and Norms (TSN)***

***Regulation of Medicines and other health technologies (RHT)***

***World Health Organization, Geneva***

© World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

*This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

## Addendum<sup>1</sup> to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1

<sup>1</sup> This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2013.

---

### **-apt-**                    **aptamers, classical and mirror ones**

(a)                    avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptetid pegol (108), olapteted pegol (109), pegaptanib (88)

(b)                    -*vaptan* stem: balovaptan (116), conivaptan (82), lixivaptan (83), mozavaptan (87), nelivaptan (98), relcovaptan (82), ribuvaptan (110), satavaptan (93), tolvaptan (83).  
Others: aptazapine (50), aptiganel (72), aptocaine (21), captamine (18), captodiame (06), captopril (39), danegaptide (101), daptomycin (58), icrocaptide (89), mercaptamine (01), mercaptomerin (01), mercaptopurine (06), naptumomab estafenatox (96), rotigaptide (94), sodium borocaptate (<sup>10</sup>B) (62), sodium stibocaptate (17), taplitumomab paptox (84)

(c)                    pegnivacogin (106)

---

### **-catib**                    **cathepsin inhibitors**

balicatib (92), dutacatib (94), odanacatib (98), petesicatib (117), relacatib (95)

---

### **-cel**                    **cell therapy**

Please refer to the Annex "General policies for cell therapies".

adimlecleucel (117), audencel (115), axicabtagene ciloleucel (117), baltaleucel (116), cenplacel (115), darvadstrocel (117), eltrapuldencel (115), emiplacel (117), evagenretcel (116), ilixadencel (116), lifileucel (118), nalotimagene carmaleucel (118), palucorcel (115), rivogenlecleucel (117), spanlecortemlocel (112 amendment in 115), tabelecleucel (117), tisagenlecleucel (117), tonongenconcel (115), vadacabtagene leraleucel (117), vandefitemcel (115)

---

### **-cetrapib**                    **cholesteryl ester transfer protein (CETP) inhibitors**

anacetrapib (98), dalcetrapib (96), evacetrapib (105), obicetrapib (115), torcetrapib (87)

---

---

**-degib**      **SMO receptor antagonists**

glasdegib (111), patidegib (111), sonidegib (107), taladegib (110), vismodegib (103)

---

**-domide**      **antineoplastics, thalidomide derivatives**

avadomide (117), endomide (40), iberdomide (117), lenalidomide (91), mitindomide (70), pomalidomide (97), thalidomide (08)

---

**-dotin**      **synthetic derivatives of dolastatin series**

amadotin: lupartumab amadotin (115)

cemadotin (75)

ixadotin: aprutumab ixadotin (115)

mafodotin: belantamab mafodotin (118), denintuzumab mafodotin (111), depatuzumab mafodotin (115), vorsetuzumab mafodotin (107)

pelidotin: cofetuzumab pelidotin (117)

soblidotin (84)

tasidotin (93)

vedotin: azintuzumab vedotin (116), brentuximab vedotin (103), enapotamab vedotin (118), enfortumab vedotin (109), glembatumumab vedotin (113), iladatuzumab vedotin (117), indusatumab vedotin (112), ladiratuzumab vedotin (117), lifastuzumab vedotin (110), losatuzumab vedotin (116), pinatuzumab vedotin (108), polatuzumab vedotin (108), samrotamab vedotin (118), sirtratumab vedotin (117), sofituzumab vedotin (110), tisotumab vedotin (113), telisotuzumab vedotin (115), vandortuzumab vedotin (113)

---

**-fenacin**      **muscarinic receptor antagonists**

afacifenacin (101), darifenacin (70), imidafenacin (90), revefenacin (114), solifenacin (85), tarafenacin (100), tofenacin (15), zamifenacin (68)

---

---

**-fensine**      **norepinephrine, serotonin, dopamine reuptake inhibitors**

brasofensine (76), diclofensine (44), liafensine (109), nomifensine (24), perafensine (44), tesofensine (89)

---

**-gepant**      **calcitonin gene-related peptide receptor antagonists**

atogepant (116), olcegepant (86), rimegepant (109), telcagepant (100), ubrogepant (109)

---

**-glurant**      **metabotropic glutamate receptor antagonists / negative allosteric modulators**

basimglurant (109), decoglurant (109), dipraglurant (102), mavoglurant (104), raseglurant (102), remeglurant (109)

---

**-imod**      immunomodulators, both stimulant/suppressive and stimulant

**-tolimod**      **toll-like receptors (TLR) agonists**

agatolimod (98), cobitolimod (113), entolimod (108), lefitolimod (113), motolimod (112), rintatolimod (102), telratolimod (118), tilsotolimod (117), vesatolimod (113)

---

**-isant**      **histamine H<sub>3</sub> receptor antagonists**

bavisant (103), cipralisant (85), enerisant (113), irdabisant (105), pitolisant (100)

---

**-laner**      **antagonists of GABA (gamma-aminobutyric acid) regulated chloride channels, antiparasitic agents**

afoxolaner (108), fluralaner (107), lotilaner (110), sarolaner (111), tigolaner (117)

---

---

**-mab**            monoclonal antibodies

**-vet-**            **veterinary use**

blontuvmab (114), frunevetmab (116), gilvetmab (116), ranevetmab (115),  
tamtuvmab (114)

---

**-nepag**            **prostaglandins receptors agonists, non-prostanoids**

(a)            aganepag (104), evatanepag (101), omidenepag (114), ralinepag (112),  
simenepag (103), taprenepag (103)

(c)            selezipag (102)

---

**-orexant**        **orexin receptor antagonists**

almorexant (98), filorexant (108), lemborexant (111), nemorexant (118),  
seltorexant (115), suvorexant (105)

---

**-prazan**        **proton pump inhibitors, not dependent on acid activation**

abeprazan (118), linaprazan (92), revaprazan (91), soraprazan (88), tegoprazan  
(113), vonoprazan (106)

---

**-rafenib**        **Raf (rapidly accelerated fibrosarcoma) kinase inhibitors**

agerafenib (115), belvarafenib (118), dabrafenib (105), encorafenib (109),  
lifirafenib (117), sorafenib (88), regorafenib (100), vemurafenib (103)

---

**-siban**            **oxytocin antagonists**

atosiban (60), barusiban (88), cligosiban (118), epelsiban (105), nolasiban  
(114), retosiban (98)

---

---

**-siran**      **small interfering RNA**

asvasiran (111), bamosiran (106), bevasiranib (108), cemdisiran (114), cosdosiran (116), fitusiran (113), givosiran (115), inclisiran (115), lumasiran (117), patisiran (109), revusiran (111), teprasiran (116), tivanisiran (116), votrisiran (117)

---

**-stat**      **enzymes inhibitors**

**-dustat**      **hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors**

daprodustat (113), desidustat (117), enarodustat (117), molidustat (108), roxadustat (108), vadadustat (114)

**-gacestat**      **gamma-secretase inhibitors**

avagacestat (104), begacestat (97), crenigacestat (117), nirogacestat (115), semagacestat (99)

---

**-tansine**      **maytansinoid derivatives, antineoplastics**

emtansine (such as laprituximab emtansine (114), naratuximab emtansine (114), trastuzumab emtansine (103))

maitansine (40)

mertansine (such as cantuzumab mertansine (105), lorvotuzumab mertansine (103))

ravtansine (such as anetumab ravtansine (109), cantuzumab ravtansine (105), coltuximab ravtansine (109), indatuximab ravtansine (105))

soravtansine (such as mirvetuximab soravtansine (113))

---

**-tide**      **peptides and glycopeptides (for special groups of peptides see -actide, -pressin, -relin, -tocin)**

**-reotide**      **somatostatin receptor agonists/antagonists**

depreotide (80), edotreotide (84), ilatreotide (68), lanreotide (64), lutetium (<sup>177</sup>Lu) oxodotreotide (116), octreotide (52), pasireotide (90), pentetreotide (66), satoreotide (115), satoreotide tetraxetan (118), satoreotide trizoxetan (114), vapreotide (62), veldoreotide (117)

**-ritide    natriuretic peptides**

anaritide (57), carperitide (65), cenderitide (105), nesiritide (80), ularitide (69)  
vosoritide (112)

---

-tinib            tyrosine kinase inhibitors

**-brutinib      agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitors**

acalabrutinib (113), evobrutinib (115), fenebrutinib (117), ibrutinib (107),  
spebrutinib (112), tirabrutinib (115), vecabrutinib (117), zanubrutinib (117)

**-citinib        Janus kinase inhibitors**

baricitinib (107), delgocitinib (117), itacitinib (115), oclacitinib (105),  
peficitinib (111), solcitinib (112), tofacitinib (105), upadacitinib (115)

**-metinib      MEK (MAPK<sup>#</sup> kinase) tyrosine kinase inhibitors**

binimetinib (109), cobimetinib (107), pexmetinib (110), ralimetinib (109),  
refametinib (106), selumetinib (100), trametinib (105)

<sup>#</sup>MAPK: mitogen activated protein kinase

---

**-traline        serotonin reuptake inhibitors**

dasotraline (110), indatraline (54), lometraline (28), sertraline (48), tametraline  
(46)

---

**-trigine        sodium channel blockers, signal transduction modulators**

elpetrigine (101), lamotrigine (52), palatrigine (58), vixotrigine (116),  
sipatrigine (74)

---

-vir              antivirals

**-asvir        antivirals, hepatitis C Virus (HCV) NS5A inhibitors**

daclatasvir (107), elbasvir (111), ledipasvir (109), odalasvir (111), ombitasvir  
(109), pibrentasvir (114), ravidasvir (113), ruzasvir (114), samatasvir (110),  
velpatasvir (112)

**- tegravir HIV integrase inhibitors**

bictegravir (113), cabotegravir (111), elvitegravir (97), raltegravir (97),  
dolutegravir (105)

---

**-xetan            chelating agents**

cabiostraxetan (103), clivatuzumab tetraxetan (113), epitumomab cituxetan (89),  
ibritumomab tiuxetan (86), lutetium (<sup>177</sup>Lu) lilotomab satetraxetan (112),  
satoreotide tetraxetan (118), satoreotide trizoxetan (114), tetraxetan (92),  
yttrium (<sup>90</sup>Y) clivatuzumab tetraxetan (102), yttrium (<sup>90</sup>Y) tacatuzumab  
tetraxetan (93)

---

**-zolid            oxazolidinone antibacterials**

cadazolid (104), contezolid (118), delpazolid (116), eperezolid (76),  
furazolidone (13), linezolid (76), posizolid (88), radezolid (99), sutezolid (106),  
tedizolid (104), vinzolidine (46)

---

**Modification of stems definitions already existing**

<b>-ast</b>	<b>anti-allergic or anti-inflammatory, not acting as anti-histaminics</b>
<b>-cept</b>	<b>Receptor molecules or membrane ligands, native, modified or synthetic</b>
<b>-fibrate</b>	<b>clofibrate derivatives, peroxisome proliferator activated receptor-<math>\alpha</math> (PPAR-<math>\alpha</math>) agonists</b>
under gli	antihyperglycaemics
<b>-glitazar</b>	<b>dual peroxisome proliferator activated receptors-<math>\alpha</math> and <math>\gamma</math> (PPAR- <math>\alpha,\gamma</math>) agonists</b>

## Annex – General policies for cell therapies

During the 61<sup>st</sup> INN Consultation in 2015, an INN-USAN-harmonized nomenclature scheme for cell therapies (CT) (shown in Table 1) was formally finalized and approved by the members of the INN Expert Group designated to deal with the selection of international nonproprietary names<sup>1</sup>.

Table 1. Nomenclature scheme for cell therapies (CT)

Prefix: random	Infix1: manipulation/s <sup>(a)</sup>	Infix2: cell type	Suffix: “-cel”
to contribute to euphonious and distinctive name, e.g.: <i>al-</i> ; <i>bet-</i> ; <i>val-</i> ...	to specify, if appropriate, which manipulation the cells have undergone, using, when available, existing infixes for manipulation <sup>(b)</sup> , e.g.: <i>-gen-</i> : transduced (genetic modification) <i>-fus-</i> : fusion to a cell	to identify the primary cell type <sup>(c)</sup> using, when available, existing infixes for cell types, e.g.: <i>-den-</i> dendritic cells <i>-mio(b)-</i> myoblasts <i>-co(n)-</i> chondrocytes <i>-fi(b)-</i> fibroblasts <i>-ker(a)-</i> keratinocytes <i>-end(o)-</i> endothelial cells <i>-leu-</i> lymphocytes/monocytes/APC (white cells) <sup>(d)</sup> ... <sup>(e)</sup>	to name <i>all</i> CT, with the <i>exception</i> of : - Minimally manipulated hematopoietic elements - Combination products

<sup>(a)</sup> There may be more than one manipulation infix in the same INN.

<sup>(b)</sup> In the case of manipulation such as cell expansion and cell activation (with cytokines/drug, etc.), there is no need for an infix, but this kind of manipulation would be specified in the description.

<sup>(c)</sup> Residual, contamination cells are not named.

<sup>(d)</sup> The cell type infix *-leu-* will be used to describe hematopoietic cell preparations that do not fit a particular or specific cell type. Such cell preparations may be comprised of a mixture of the various blood cell elements, a subset of blood elements such as T- B- or NK-cells, or antigen presenting cells (APCs) that do not fit the definition of dendritic cells fall into this category.

<sup>(e)</sup> **-ubi-** (previous nomenclature scheme: **-cor-**) for *umbilical cord cells*; **-ep(a)-** for *hepatocytes*; **-isle-** for *islet cells*; **-mestro-** for *mesenchymal stromal cells (msc)*; **-ova-** for *ovary cells*; **-pla(c)-** for *placenta cells*; **-ret-** for *retinal epithelial cells*; **-ren-** for *renal tubular cells*; **-ur-** for *urothelial cells*; **-tem-** for *stem cells*; **-defitem-** for *differentiated stem cells* (not fitting into any existing category); **-tesi-** for *testis cells*; **-tu-** for *tumor cells*.

**Note:** Information concerning manipulations and/or modifications, and the type of the CT (i.e. allogeneic, autologous and xenogeneic) would be specified in the description of the substance.

<sup>1</sup> INN selected before the adoption of the present nomenclature scheme may follow different rules.